Navigation Links
ResMed Inc. Announces Record Financial Results For The Quarter Ended And Nine Months Ended March 31, 2013
Date:4/25/2013

an.  

For the nine months ended March 31, 2013, revenue was $1.1 billion, an increase of 10% over the nine months ended March 31, 2012 (a 12% increase on a constant currency basis).  For the nine months ended March 31, 2013, income from operations and net income were $268.7 million and $234.1 million, an increase of 31% and 32%, respectively, compared to the nine months ended March 31, 2012.  Diluted earnings per share for the nine months ended March 31, 2013 were $1.60 per diluted share, an increase of 36% compared to the nine months ended March 31, 2012.

Inventory, at $166.5 million, decreased by $7.9 million compared to June 30, 2012.  Accounts receivable days sales outstanding, at 67 days, decreased by 1 day compared to June 30, 2012.

Additionally, the Board of Directors has today declared a quarterly dividend of $0.17 per share, which will have a record date of May 21, 2013, and be payable on June 18, 2013.  The dividend will be paid in U.S. currency to holders of ResMed's common stock trading on the New York Stock Exchange (NYSE).  Holders of CHESS Depositary Instruments (CDIs) trading on the Australian Securities Exchange will receive an equivalent amount in Australian currency, based on the exchange rate on the record date, and reflecting the 10:1 ratio between CDIs and NYSE shares.  Because the two exchanges have different settlement and transfer procedures, the ex-dividend periods before the record date will be different for common stock and for CDIs.  The ex-dividend date will be May 15, 2013 for CDI holders and May 17, 2013 for common stock holders. As a result of these differences, ResMed has received a waiver from the ASX's settlement operating rules, which will allow R
'/>"/>

SOURCE ResMed Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. ResMed Noninvasive Ventilation Device Cleared by FDA for COPD Treatment
2. ResMed Announces Conference Call And Webcast To Discuss Third Quarter 2013 Results
3. ResMed Takes Action to Enforce Patents
4. Buoyed by Forecasts, Where 2013 Leads - Research Report on ResMed Inc., Zimmer Holdings, Inc., Waters Corporation, Covidien PLC, and Medtronic, Inc.
5. ResMed Inc. Announces Record Financial Results For The Quarter Ended And Six Months Ended December 31, 2012
6. ResMed Inc. Announces Exchange Rate For Upcoming Dividend Payment
7. ResMed Inc. Announces Record Financial Results for the Quarter Ended September 30, 2012
8. ResMed Inc. Announces Record Financial Results For The Quarter And Twelve Months Ended June 30, 2012
9. ResMed Announces Conference Call And Webcast To Discuss Fourth Quarter And Fiscal Year-End 2012 Results
10. ResMed Launches Narval™ CC Mandibular Repositioning Device in the US
11. ResMed Inc. Announces Plan To Initiate Dividend And Update On Chief Executive Officer Succession
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... N.J. , July 22, 2014  Vernalis plc ... achievement of proof-of-concept (POC) for CCP-08, the third ... prescription cough cold collaboration. Under this collaboration, POC ... a successful human pilot comparative study against an ... achieving POC, Vernalis will make a milestone payment ...
(Date:7/21/2014)... 2014 McCord Research, Inc. was recently ... 8,796,315). This patent describes a method for accelerating ... the inventor, Dr. McCord, this method includes administering ... a composition of an effective amount of hydroxytyrosol ... blood, such that the administration of the combination ...
(Date:7/21/2014)... July 21, 2014  EHE International, the recognized leader ... nationwide physician network, today announced that Dignity Health Medical ... has been named an EHE-certified preventive care ... Las Vegas region now have greater access ... their health. "EHE is proud to ...
Breaking Medicine Technology:Third Product in Vernalis' Cough Cold Pipeline (CCP-08) Achieves Proof-of-Concept 2Third Product in Vernalis' Cough Cold Pipeline (CCP-08) Achieves Proof-of-Concept 3US Patent Office Grants McCord Research Endothelial Cell Treatment Patent 2EHE International Certifies Dignity Health Medical Group Nevada, LLC as Its Newest Partner 2
... Acute Myeloid ... ... the U.S. Food & Drug Administration (FDA) has granted orphan,drug designation ... (AML)., Celator is currently preparing to conduct two randomized Phase ...
... in ,The Lancet, and Presented at ESC Congress-, ... new international,study, the GISSI Heart Failure (GISSI-HF) study, ... esters reduced all cause mortality and hospital,admissions for ... findings are published in this week,s online version ...
Cached Medicine Technology:Celator Pharmaceuticals Receives Orphan Drug Designation for Anticancer Agent CPX-351 2New Data Shows Prescription Omega-3 Acid Ethyl Esters Reduced the Incidence of Death in Heart Failure Patients 2New Data Shows Prescription Omega-3 Acid Ethyl Esters Reduced the Incidence of Death in Heart Failure Patients 3New Data Shows Prescription Omega-3 Acid Ethyl Esters Reduced the Incidence of Death in Heart Failure Patients 4
(Date:7/22/2014)... Steven Reinberg HealthDay Reporter ... tests may one day help predict survival and the course ... also called Lou Gehrig,s disease, Italian researchers report. , , ... how fast ALS is progressing are called albumin and creatinine. ... health, according to the U.S. National Library of Medicine. ...
(Date:7/22/2014)... Boston University School of Medicine (BUSM) and Boston ... received care through BMC,s Violence Intervention Advocacy Program ... and social needs of violently injured youthswere less ... life changing behaviors through connections to caring, steady, ... hope. These findings are reported in the journal ...
(Date:7/22/2014)... The European Bio stimulants Market report defines and segments ... forecast of revenue. The bio stimulants market in Europe ... 2013 to $940.6 million by 2018, at a CAGR ... the TOC of the Europe Bio stimulants Market report, ... , http://www.micromarketmonitor.com/market/europe-bio-stimulants-1315565884.html , Agriculture contributes to 10% ...
(Date:7/22/2014)... California (PRWEB) July 22, 2014 In ... women in recovery, the Marinello School of Beauty joined ... Addiction Treatment Center for a free “Make-over Day.” ... to be of service to the community, and The ... and renewed. They also gained some first-hand experience about ...
(Date:7/22/2014)... Ipswich, Mass. (PRWEB) July 22, 2014 ... of EBSCO Information Services , announces the ... to assist occupational health and safety professionals employed ... of chemicals and need to manage the impact ... , PoisonEXPERT provides access to relevant chemical-specific information ...
Breaking Medicine News(10 mins):Health News:Blood Test Might Help Predict Survival With Lou Gehrig's Disease 2Health News:Blood Test Might Help Predict Survival With Lou Gehrig's Disease 3Health News:Clients of BMC's violence interventional advocacy program find experience supportive 2Health News:Clients of BMC's violence interventional advocacy program find experience supportive 3Health News:Europe Bio Stimulants Market is Expected to Reach $940.6 Million in 2018 - New Report by MicroMarket Monitor 2Health News:Europe Bio Stimulants Market is Expected to Reach $940.6 Million in 2018 - New Report by MicroMarket Monitor 3Health News:Europe Bio Stimulants Market is Expected to Reach $940.6 Million in 2018 - New Report by MicroMarket Monitor 4Health News:Europe Bio Stimulants Market is Expected to Reach $940.6 Million in 2018 - New Report by MicroMarket Monitor 5Health News:The Discovery House 'Make-over Day' Adds Pampering To Recovery 2Health News:The Discovery House 'Make-over Day' Adds Pampering To Recovery 3Health News:PoisonEXPERT™ from ExPub Now Available 2Health News:PoisonEXPERT™ from ExPub Now Available 3
... FALLS CHURCH, Va. and CUMMAQUID, Mass., April ... with research analysis partner Cambashi Ltd, today invited,medical ... on current industry,challenges and practices. The survey asks ... and applications, and,performance., The research team is ...
... function, researchers report , , WEDNESDAY, April 23 (HealthDay News) -- ... embryonic stem cells into three types of human heart muscle ... in mice. , The findings have a number of implications, ... cells to test drugs. , "We have now a supply ...
... 2008 Shire plc (LSE: SHP, NASDAQ: SHPGY,), the global ... approval from the U.S. Food and Drug Administration (FDA) ... Deficit Hyperactivity Disorder (ADHD) in adults. VYVANSE, introduced ... children aged 6 to 12 years, is now the ...
... Florida,s elected leaders,received a message from thousands ... Governor Charlie Crist and legislative leaders not to,eliminate ... the state,s most,vulnerable citizens., Driven by ambulance ... gurney,the petitions ask Governor Crist, Senate President Ken ...
... announces the following Webcast:, What: Heska Corporation Invites You to ... Stockholders on the Web, When: Tuesday, May 6, @ 9:00 ... Stockholders link on the front ... Simply log on to the web at the ...
... Germany of a myocardial infarction is not higher for ... Deutsches rzteblatt International (Dtsch Arztebl Int 2008; 105(15): 279-85), ... disproved this widely held view. , ( http://www.aerzteblatt-international.de/v4/archiv/pdf.asp?id=59860 ... medical data from AOK (a large general statutory health ...
Cached Medicine News:Health News:Risk Management: Best Practices for Medical Device Profitability 2Health News:Embryonic Stem Cells Turned Into Three Types of Heart Cells 2Health News:FDA approves VYVANSE, first and only once-daily prodrug stimulant to treat ADHD in adults 2Health News:FDA approves VYVANSE, first and only once-daily prodrug stimulant to treat ADHD in adults 3Health News:FDA approves VYVANSE, first and only once-daily prodrug stimulant to treat ADHD in adults 4Health News:Thousands Sign Petitions Urging Governor Crist and Legislative Leaders to Save Healthcare Coverage for 40,000 Floridians 2Health News:Thousands Sign Petitions Urging Governor Crist and Legislative Leaders to Save Healthcare Coverage for 40,000 Floridians 3Health News:Webcast Alert: Heska Corporation's Annual Meeting of Stockholders Webcast 2
... Adams compact II centrifuge ... small laboratory. Attached, durable cover ... seals to minimize aerosol emissions, ... low temperature rise, brushless motor, ...
... Powerful ventilated floor-standing centrifuge. Mobile space ... large choice of accessories, analog controls, ... & shutdown (JOUAN patented pendulum system), ... and temperature limitation, rugged motor, tough ...
... utilize the infinity-corrected optical system ... in cell checking. The CKX31 ... suited to routine applications in ... culture and embryology to immunology ...
Continuous rocking motion graphic display....
Medicine Products: